natgillin/translations-raw huggingface dataset:
Plenadren, given once per day, was compared with conventional hydrocortisone treatment, which is given three times per day.
Zdravilo Plenadren, ki se daje enkrat na dan, so primerjali s konvencionalnim hidrokortizonskim zdravljenjem, ki se daje trikrat na dan.
The most common side effects with Plenadren (seen in more than 1 patient in 10) are fatigue (tiredness), diarrhoea, vertigo (feeling dizzy) and headache.
Najpogostejši neželeni učinki zdravila Plenadren (opaženi pri več kot 1 bolniku od 10) so utrujenost, driska, omotica in glavobol.
Plenadren is a medicine used to treat adrenal insufficiency in adults.
Plenadren je zdravilo, ki se uporablja za zdravljenje adrenalne insuficience pri odraslih.
The full EPAR for Plenadren can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Plenadren je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
For practical information about using Plenadren, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Plenadren naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions with Plenadren, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Plenadren glejte navodilo za uporabo.
The active substance in Plenadren, hydrocortisone, is the pharmaceutical form of cortisol, the main steroid hormone secreted by the adrenal gland.
Zdravilna učinkovina v zdravilu Plenadren, hidrokortizon, je farmacevtska oblika kortizola, tj. glavnega steroidnega hormona, ki ga izloča nadledvična žleza.
Hydrocortisone replaces the natural cortisol that is missing in patients with adrenal insufficiency.
Hidrokortizon nadomešča naravni kortizol, ki ga primanjkuje ljudem z adrenalno insuficienco.
In patients taking Plenadren the cortisol levels achieved were considered to be satisfactory for patients with adrenal insufficiency.
Pri bolnikih, ki so jemali zdravilo Plenadren, so bile dosežene ravni kortizola ocenjene kot zadovoljive za bolnike z adrenalno insuficienco.
Plenadren contains the active substance hydrocortisone.
Zdravilo Plenadren vsebuje zdravilno učinkovino hidrokortizon.
How does Plenadren work?
Kako zdravilo Plenadren deluje?
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Plenadren achieved satisfactory levels of cortisol during the treatment of patients with adrenal insufficiency.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je menil, da so pri zdravljenju bolnikov z adrenalno insuficienco ravni kortizola, dosežene z zdravilom Plenadren, zadovoljive.
How is Plenadren used?
Kako se zdravilo Plenadren uporablja?
The usual daily dose ranges from 20 to 30 mg, once per day early in the morning; tablets should be swallowed whole with a glass of water at least 30 minutes before food.
Običajni odmerek je od 20 do 30 mg enkrat na dan zgodaj zjutraj.
Because it is available as a modified-release tablet, Plenadren releases hydrocortisone over a longer period of time allowing for a once-daily dosing.
Ker je zdravilo Plenadren na voljo v obliki tablet s prirejenim sproščanjem, se hidrokortizol sprošča dlje, kar omogoča jemanje zdravila samo enkrat na dan.
Although once daily dosing comes with a risk of cortisol levels being too low in the afternoon, this can be managed by adding further doses of hydrocortisone if needed.
Prav tako je ugotovil, da je zdravilo priročno zaradi odmerjanja enkrat na dan. Odmerki enkrat na dan sicer lahko pomenijo tveganje za prenizke ravni kortizola v popoldanskih urah, kar pa je mogoče uravnati z dodatnimi odmerki hidrokortizola po potrebi.
Plenadren can only be obtained with a prescription.
Predpisovanje in izdaja zdravila je le na recept.
Ristfor is taken twice a day.
Zdravilo Ristfor se jemlje dvakrat na dan.
What measures are being taken to ensure the safe and effective use of Ristfor?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ristfor?
The full EPAR for Ristfor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ristfor je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Ristfor on 15 March 2010.
Evropska komisija je dovoljenje za promet z zdravilom Ristfor, veljavno po vsej Evropski uniji, izdala 15. marca 2010.
Sitagliptin has been authorised in the European Union (EU) as Januvia and Xelevia since 2007 and as Tesavel since 2008.
V Evropski uniji (EU) je bil odobren pod imenoma Januvia in Xelevia od leta 2007 in pod imenom Tesavel od leta 2008.
The results of three further studies were used to support the use of Ristfor.
Rezultati treh nadaljnjih študij so bili uporabljeni v podporo uporabi zdravila Ristfor.
What benefit has Ristfor shown during the studies?
Kakšne koristi je zdravilo Ristfor izkazalo med študijami?
Ristfor sitagliptin / metformin hydrochloride
Ristfor sitagliptin/metforminijev klorid
Sitagliptin is a dipeptidyl-peptidase-4 (DPP 4) inhibitor.
Sitagliptin je zaviralec dipeptidil-peptidaze-4 (DPP 4).
The strength of tablet to use depends on the dose of the other diabetes medicines that the patient was taking before.
Jakost tablete, ki jo je treba uporabiti, je odvisna od odmerka drugih zdravil za sladkorno bolezen, ki ga je bolnik jemal prej.
This authorisation was based on the authorisation granted to Janumet in 2008 (‘informed consent').
Izdaja tega dovoljenja je temeljila na dovoljenju za promet za zdravilo Janumet, ki je bilo izdano leta 2008 (uporaba dokumentacije s soglasjem).
For more information about treatment with Ristfor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Ristfor preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP decided that Ristfor's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Ristfor večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
A risk management plan has been developed to ensure that Ristfor is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Ristfor je bil pripravljen načrt obvladovanja tveganj.
It is used in addition to diet and exercise in the following ways:
Uporablja se kot dodatek k prehrani in telesni vadbi, in sicer:
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ristfor.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about Ristfor:
Druge informacije o zdravilu Ristfor:
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ristfor, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za to zdravilo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
It is available as tablets (50 mg sitagliptin and 850 mg metformin hydrochloride; 50 mg sitagliptin and 1,000 mg metformin hydrochloride).
Na voljo je v obliki tablet (50 mg sitagliptina/850 mg metforminijevega klorida in 50 mg sitaglipina/1 000 mg metforminijevega klorida).
Why has Ristfor been approved?
Zakaj je bilo zdravilo Ristfor odobreno?
What is the risk associated with Ristfor?
Kakšna tveganja so povezana z zdravilom Ristfor?
Ristfor must not be used in patients who have diabetic ketoacidosis or pre coma (dangerous conditions that can occur in diabetes), problems with the kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack.
Zdravilo Ristfor se ne sme uporabljati pri bolnikih, ki imajo diabetično ketoacidozo, predkomo (nevarno stanje, ki se lahko pojavi pri sladkorni bolezni), težave z ledvicami ali jetri, obolenja, ki lahko prizadenejo ledvice, ali obolenja, ki povzročajo zmanjšano oskrbo tkiv s kisikom, kot so srčno popuščanje, težave s pljuči ali nedavni srčni napad.
The company presented the results of three studies of Januvia/Xelevia to support the use of Ristfor in patients who were not satisfactorily controlled on their existing metformin treatment.
Družba je predstavila rezultate treh študij z zdraviloma Januvia/Xelevia v podporo uporabi zdravila Ristfor pri bolnikih, pri katerih obstoječe zdravljenje z metforminom ni zadostno za nadzor bolezni.
This document is a summary of the European Public Assessment Report (EPAR) for Ristfor.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ristfor.
• in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin
• v kombinaciji s sulfonilsečnino, agonistom PPAR gama, kot je tiazolidinedion, ali insulinom (tj.
The effectiveness of adding sitagliptin to metformin was similar to that of adding glipizide.
Učinkovitost dodajanja sitagliptina metforminu je bila podobna kot pri dodajanju glipizida.
Ristfor should be taken with food to avoid any stomach problems caused by metformin.
Zdravilo Ristfor je treba jemati s hrano, da se preprečijo želodčne težave, ki jih povzroča metformin.
Ristfor was more effective than metformin alone.
Zdravilo Ristfor je bilo učinkovitejše od metformina samega.
Sitagliptin does not work when the blood glucose is low.
Sitagliptin ne deluje, če je raven glukoze v krvi nizka.
Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut.
Metformin deluje predvsem z zaviranjem tvorbe glukoze in zmanjševanjem njene absorpcije v črevesju.
The company carried out additional studies to show that the active substances in Ristfor are absorbed by the body in the same way as the two medicines given separately.
Družba je opravila še nadaljnje študije, da bi dokazala, da telo zdravilni učinkovini zdravila Ristfor absorbira na enak način, kot če sta vzeti v obliki ločenih zdravil.
If Ristfor is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).
Če se zdravilo Ristfor jemlje skupaj s sulfonilsečnino ali insulinom, bo morda treba odmerek sulfonilsečnine ali insulina zmanjšati, da ne bi prišlo do hipoglikemije (nizkih ravni sladkorja v krvi).
As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type 2 diabetes.
Kot posledica delovanja obeh zdravilnih učinkovin se raven glukoze v krvi zniža, to pa prispeva k nadzoru sladkorne bolezni tipa 2.
Serious side effects reported with Ristfor include pancreatitis (inflammation of the pancreas) and hypersensitivity (allergic reactions).
Med resnimi neželenimi učinki, o katerih so poročali pri uporabi zdravila Ristfor sta pankreatitis (vnetje trebušne slinavke) in preobčutljivostne (alergijske) reakcije.
Ristfor is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Zdravilo Ristfor se uporablja za zdravljenje bolnikov s sladkorno boleznijo tipa 2 za izboljšanje nadzora nad ravnjo glukoze (sladkorja) v krvi.
Ristfor is a diabetes medicine that contains two active substances, sitagliptin and metformin hydrochloride.
Ristfor je zdravilo, ki vsebuje dve zdravilni učinkovini, sitagliptin in metforminijev klorid.
In the first of the three further studies, Ristfor was more effective than metformin or sitagliptin alone.
V prvi od treh dodatnih študij je bilo zdravilo Ristfor učinkovitejše od metformina ali sitagliptina samega.
(other types of diabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin.
drugimi vrstami zdravil za sladkorno bolezen) pri bolnikih, pri katerih bolezen ni zadostno nadzorovana s kombinacijo enega od teh zdravil in metformina.
The second included 278 patients who were not satisfactorily controlled on the combination of metformin and rosiglitazone (a PPAR-gamma agonist) and compared the effects of adding sitagliptin or placebo.
V drugo je bilo vključenih 278 bolnikov, pri katerih nadzor s kombinacijo metformina in rosiglitazona (agonista PPAR gama) ni bil zadosten, v njej pa so primerjali učinke dodajanja sitagliptina ali placeba.
Hypoglycaemia has been reported in combination with a sulphonylurea in 13.8% of patients and with insulin in 10.9% of patients.
V kombinaciji s sulfonilsečnino je prišlo do hipoglikemije pri 13,8 % bolnikov, v kombinaciji z insulinom pa pri 10,9 % bolnikov.
The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Ristfor with that of metformin or sitagliptin alone.
V prvo je bilo vključenih 1 091 bolnikov, pri katerih zadosten nadzor ni bil dosežen zgolj z dieto in telesno vadbo, v njej pa so primerjali učinke zdravila Ristfor z učinki metformina ali sitagliptina, uporabljenih samostojno.
Two of the studies looked at sitagliptin as an add-on to metformin: the first compared it with placebo (a dummy treatment) in 701 patients, and the second compared it with glipizide (a sulphonylurea) in 1,172 patients.
V dveh študijah so proučevali sitagliptin kot dodatek metforminu: v prvi so ga pri 701 bolniku primerjali s placebom (zdravilom brez zdravilne učinkovine), v drugi pa z glipizidom (sulfonilsečnino) pri 1 172 bolnikih.
The active substances in Ristfor, sitagliptin and metformin hydrochloride, each have a different mode of action.
Zdravilni učinkovini v zdravilu Ristfor, sitagliptin in metforminijev klorid, imata različna načina delovanja.
In the second, HbA1c levels were reduced by 1.03% after 18 weeks in patients adding sitagliptin to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
V drugi študiji so bile ravni HbA1c znižane za 1,03 % po 18 tednih pri bolnikih, ki so sitagliptin dodajali metforminu in rosiglitazonu, v primerjavi s padcem za 0,31 % pri tistih, ki so kot dodatek prejemali placebo.
What is Ristfor used for?
Za kaj se zdravilo Ristfor uporablja?
Adding 100 mg sitagliptin to metformin reduced HbA1c levels by 0.67% (from around 8.0%) after 24 weeks, compared with a fall of 0.02% in the patients adding placebo.
Z dodajanjem 100 mg sitagliptina k metforminu so se ravni HbA1c po 24 tednih znižale za 0,67 % (z okoli 8,0 %) v primerjavi z znižanjem za 0,02 % pri bolnikih, ki so kot dodatek prejemali placebo.
In the study in which sitagliptin was added to glimepiride and metformin, the levels of HbA1c were reduced by 0.59% after 24 weeks, compared with an increase of 0.30% in the patients adding placebo.
V študiji, pri kateri se je sitagliptin dodajal glimepiridu in metforminu, so se ravni HbA1c po 24 tednih znižale za 0,59 % v primerjavi s povečanjem za 0,30 % pri bolnikih, ki so kot dodatek prejemali placebo.
How has Ristfor been studied?
Kako je bilo zdravilo Ristfor raziskano?
For the full list of all side effects reported with Ristfor, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ristfor, glejte navodilo za uporabo.
• in patients who are not satisfactorily controlled on metformin (a diabetes medicine) used on its own;
• pri bolnikih, pri katerih sladkorna bolezen ni zadostno nadzorovana samo z metforminom
How is Ristfor used?
Kako se zdravilo Ristfor uporablja?
Finally, they were reduced by 0.59% after 24 weeks in patients adding sitagliptin to insulin, compared with a fall of 0.03% in those adding placebo.
V zadnji študiji pa so bile po 24 tednih znižane za 0,59 % pri bolnikih, ki so insulinu dodajali sitagliptin, v primerjavi z znižanjem za 0,03 % pri bolnikih, ki so kot dodatek prejemali placebo.
How does Ristfor work?
Kako zdravilo Ristfor deluje?
The second injection is given three to four weeks later.
Druga injekcija se da tri do štiri tedne pozneje.
There can be a slight rise in body temperature, usually no more than 1 °C, in the 24 hours following vaccination.
Pojavi se lahko tudi rahlo povišanje telesne temperature, navadno za največ 1°C, v 24 urah po cepljenju.
Vaccination may be followed by a small local swelling at the injection site, which normally resolves within five weeks.
Po cepljenju se lahko pojavi majhna oteklina na mestu injiciranja, ki navadno izgine v petih tednih.
Two studies were conducted in sheep and cattle to establish the period of protection provided by the vaccine.
Dve študiji sta bili izvedeni pri ovcah in govedu za določitev obdobja zaščite, ki ga zagotavlja cepivo.
The vaccine is used to prevent viraemia (the presence of viruses in the blood) and reduce the signs of the disease.
Cepivo se uporablja za preprečitev viremije (prisotnosti virusov v krvi) in zmanjšanje znakov bolezni.
The duration of protection of the vaccine in both sheep and cattle was found to be 12 months.
Zaščita po cepljenju pri ovcah in govedu znaša 12 mesecev.
The studies also showed that the vaccine can be used in pregnant sheep and cattle as well as lactating cattle.
Študije so pokazale tudi, da se cepivo lahko uporabi pri brejih ovcah in kravah ter pri molznih kravah.
The European Commission granted a marketing authorisation valid throughout the European Union, for BTVPUR AlSap 1 on 17 December 2010.
Evropska komisija je dovoljenje za promet s cepivom BTVPUR AlSap 1, veljavno po vsej Evropski uniji, odobrila dne 17. decembra 2010.
In 2013 the CVMP considered that the submitted data were adequate for the authorisation of BTVPUR AlSap 1 to convert to a normal status.
Leta 2013 je CVMP menil, da predloženi podatki zadostujejo, da dovoljenje za promet s cepivom BTVPUR AlSap 1 dobi običajen status.
The withdrawal period for BTVPUR AlSap 1 for meat and milk for cattle and sheep is zero days.
Obdobje karence za cepivo BTVPUR AlSap 1 za meso in mleko pri govedu in ovcah je nič dni.
In the future, if the animals are exposed to the bluetongue virus, their immune system will be able to produce antibodies more quickly.
Ob ponovni izpostavitvi virusu bolezni modrikastega jezika v prihodnosti bo imunski sistem tako hitreje tvoril protitelesa.
The first injection is given from one month of age in animals that have never been exposed to the disease, and from two-and-a-half months if the animal's mother is already immune to the disease.
Živalim, ki še nikoli niso bile izpostavljene bolezni, se da prva injekcija od enega meseca starosti, mladičem mater, ki so že imune na bolezen, pa od 2,5 meseca starosti.
The studies showed that the vaccine is safe for sheep and cattle and that it reduces the signs of the disease and prevents viraemia in animals from one month of age that are infected with bluetongue virus serotype 1.
Študije so pokazale, da je cepivo varno za uporabo pri ovcah in govedu ter da zmanjšuje simptome bolezni in preprečuje viremijo pri živalih, starejših od enega meseca, ki so okužene s serotipom 1 virusa bolezni modrikastega jezika.
The safety of the vaccine was studied in two main overdose laboratory safety studies carried out in sheep and cattle.
Varnost cepiva so proučevali v dveh glavnih laboratorijskih študijah varnosti glede prevelikega odmerjanja, ki so ju opravili pri ovcah in govedu.
When it is given to sheep and cattle, the animals' immune systems recognise the viruses as ‘foreign' and make antibodies against them.
Ko ovce in govedo prejmejo cepivo, njihov imunski sistem viruse prepozna kot „tujke“ in proti njim razvije protitelesa.
The company also presented results from a series of trials conducted with vaccines of similar composition but including different serotypes from the one in BTVPUR AlSap 1 in order to extrapolate further conclusions on the effectiveness of the vaccine.
Družba je predstavila tudi rezultate niza preskušanj, izvedenih s cepivi s podobno sestavo, ki pa so vključevali serotipe, drugačne od serotipa v cepivu BTVPUR AlSap 1, da bi pridobili nadaljnje zaključke o učinkovitosti cepiva.
Results also from a series of laboratory safety trials performed with vaccines of similar composition but including different bluetongue serotypes (including studies in pregnant ewes and cows) were presented in order to extrapolate safety conclusions.
Predloženi so bili tudi rezultati niza laboratorijskih preskušanj varnosti s cepivi s podobno sestavo, vendar drugačnimi serotipi virusa modrikastega jezika (vključno s študijami pri brejih ovcah in kravah), da bi pridobili zaključke o varnosti.
The effectiveness of the vaccine was studied in three main laboratory trials using a vaccine with bluetongue serotype 1 in sheep and cattle of young age.
Učinkovitost cepiva so proučevali v treh glavnih laboratorijskih preskušanjih z uporabo cepiva, ki vsebujejo virus modrikastega jezika, serotip 1, pri mladih ovcah in govedu.
BTVPUR AlSap 1 was initially authorised under ‘exceptional circumstances'.
Cepivo BTVPUR AlSap 1 je prvotno pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
The benefitrisk balance may be found in the scientific discussion module of this EPAR.
Za razmerje med koristmi in tveganji glejte modul o znanstveni razpravi tega evropskega javnega poročila o oceni zdravila (EPAR).
BTVPUR AlSap 1 is a vaccinethat is available as a suspension for injection.
Zdravilo BTVPUR AlSap 1 je cepivo, ki je na voljo v obliki suspenzije za injiciranje.
BTVPUR AlSap 1 contains bluetongue virus of one types (‘serotype 1').
Cepivo BTVPUR AlSap 1 vsebuje en tip virusa modrikastega jezika („serotip 1“).
Inactivated adjuvanted vaccine against bluetongue disease virus serotype 1
inaktivirano cepivo z adjuvansom proti virusu modrikastega jezika, serotip 1
BTVPUR AlSap 1 is a vaccine.
Zdravilo BTVPUR AlSap 1 je cepivo.
The CVMP concluded that the benefits of BTVPUR AlSap 1 exceed the risks for active immunisation of sheep and cattle to prevent infection, viraemia and clinical signs caused by the bluetongue virus serotype 1, and recommended that BTVPUR AlSap 1 be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi cepiva BTVPUR AlSap 1 za aktivno imunizacijo ovac in goveda za preprečitev okužbe, viremije in kliničnih znakov, ki jih povzroča serotip 1 virusa bolezni modrikastega jezika, večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
What benefit has BTVPUR AlSap 1 shown during the studies?
Kakšne koristi je zdravilo BTVPUR AlSap 1 izkazalo med študijami?
BTVPUR AlSap 1 is used in sheep and cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges..
Cepivo BTVPUR AlSap 1 se uporablja pri ovcah in govedu za zaščito pred boleznijo modrikastega jezika, tj. okužbo, ki jo prenašajo trzače, povzroča pa jo virus modrikastega jezika.
Other information about BTVPUR AlSap 1:
Druge informacije o zdravilu BTVPUR AlSap 1:
It contains inactivated (killed) bluetongue serotype 1 virus.
Vsebuje inaktivirane (uničene) viruse modrikastega jezika, serotip 1.
BTVPUR AlSap 1 contains a bluetongue virus that has been inactivated so that it cannot cause the disease.
Cepivo BTVPUR AlSap 1 vsebuje inaktivirani virus bolezni modrikastega jezika, ki ne povzroča bolezni.
What is the risk associated with BTVPUR AlSap 1?
Kakšna tveganja so povezana z zdravilom BTVPUR AlSap 1?
Why has BTVPUR AlSap 1 been approved?
Zakaj je bilo zdravilo BTVPUR AlSap 1 odobreno?
What is BTVPUR AlSap 1 used for?
Za kaj se zdravilo BTVPUR AlSap 1 uporablja?